Heart Metabolics bargain with the FDA for a single Phase III

15/04/2015 - 2 minutes

Heart Metabolics received an agreement letter from the FDA related to the company’s proposed phase III trial Special Protocol Assessment (SPA) request. The FDA has agreed to a single, randomized, pivotal Phase III trial of 350 patients evaluating perhexiline for the treatment of moderate-to-severe hypertrophic cardiomyopathy (HCM).

The company, focused on the development of drugs for orphan diseases including HCM, has also appointed William Daly as President and Chief Executive Officer and member of the board of directors, and Dr. Gregory Ayers as Chief Medical Officer.

Mr. Daly has more than 20 years of experience in the biotech industry as an industry executive and an investment banker. In addition to his most recent role at Puma Biotechnology, he has worked in business development and operations roles at several companies, including Johnson & Johnson (Ortho Biotech), Allergan and Akebia Therapeutics.

Dr. Corey Goodman, Chair of Heart Metabolics and Managing Partner at venBio, said: “Securing this SPA agreement is a key piece of our strategic plan to rapidly advance perhexiline through the final stages of clinical development.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!